López MJA, Bazán BA, Delgado CMM, González GA, Portilla FVH, Morales LE

Language: Spanish
References: 11
Page: 14-17
PDF size: 854.05 Kb.

ABSTRACT

The loss of the kidney in the transplant is associated to various factors such as the surgery, factors of the donor and the receiver, the experience of the surgery team and the inmunological suppression. We present a retrospective study with our groups, in 12 years of experience in our service in the Hospital Juárez de México; evaluating the grafts losses between live (LD) and dead donors (DD). We included 150 cases (99 LD and 51 DD); the mean life expectations were at 1, 3 and 5 years of 95.5%, 87.7% and 86.6%, respectively. There were 17 grafts loss (11.3%), being the principal reasons the inmunological rejection and the vascular thrombosis without significant difference between these groups. The mean life surviving of the graft was 98% for the LD at 1 year, 93.7% to 3 years and 90.5% for 5 years; and for the DD 96% at 1 year, 91% for 3 years and 89% for 5 years.

REFERENCES

1. González MM, García BJM. Trasplante renal. 1a. Ed. Madrid, España: Ed. Princeps; 2000, p. XV.

2. Holm CA, Jiménez DA, Hernández MB, Camarena AA, et al. Trasplante renal de donador vivo relacionado y donador de cadáver: Experiencia con 500 casos. Cir Gen 2002; 24(2): 116-23.

3. Gómez UP, Zarragza S, Amenabar JJ, Urbizu JA, et al. Evolución de las causas de pérdida de injerto renal en el periodo 1980-1998. Rev Esp Nef 2000; 36(1): 79-81.

4. Danovitch GM. Trasplante renal. 3a. Ed. Madrid, España: Ed. Marbán; 2002, p. 1-16.

5. National Kidney Foundation. Primer On Kidney Diseases. 3a. Ed. Canadá: Academic Press; 2001 (68), p. 460-70.

6. Danovitch GM. Immunosuppressive medications for renal transplantation: A multiple choice question. Kidn Int 2001; 59: 388-402.

7. Herwig ULF, Meier K, Akinlolu O, et al. Effect of mycophenolate mofetil long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000; 11: 2366-70.

8. Yves V. The art of inmunosuppression: Tailoring therapy for the future. Trans Proc 2001; 33(5): 1-7.

9. Jannifer L, Pharm D, Velez R. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharm 1999; 19: 1127-37.

10. Roy FM, Alloway R, Pharm D, et al. Generic drug substitution in transplantation: Examples from the epic of cyclosporine development. Dial Trans 2000; 29(5): 260-7.

11. Scharer K, Feneberg R, Klaus G, et al. Experience 14 with deflazacort in children and adolescents after renal transplantation. Pediatric Nephrol 2000; p. 457-63.